LOL I added also at the same $8.57. I emailed the company about that negative article and their response and if there is any truth to the glitches?
from the article: Conclusion
"I believe LF has three unique characteristics that makes it a compelling investment: 1) the company is in excellent financial health and has the resources to take it on the chin a few times before going down, 2) the company has hidden assets such as its strong brand name and a trove of top-tier educational content that are not being considered by the market, and 3) the company adopted and is successfully executing the right strategy.
In my opinion, LF is worth at least $1 billion, and its current market value is suggesting that the company is undervalued by at least 40% - this is a margin of safety hard to find these days."
They were "automatic sales" and "Automatic sales are insignificant because they’re scheduled at intervals established far in advance and are simply done to generate income for the insider over time."
is the Yahoo average estimates for next year based on 3 analysts. A 20 p/e would price this at around $10, based on next year's .53 estimates.
Sentiment: Strong Buy
a downgrade by Piper Jaffrey....totally dumb....they have an $8 price target with no reason for the downgrade given and we have a great award winning product.
sorry it wasn't Piper Jaffray it was: Analysts at Ascendiant Capital downgraded Leapfrog Enterprises (NYSE: LF) from â€œbuyâ€ to â€œneutral.â€ The target price for Leapfrog Enterprises has been lowered from $12 to $8. Leapfrog's shares closed at $9.15 yesterday.
from the article http://finance.yahoo.com/news/synta-pharma-slumps-data-cancer-194755607.html
LF: "Time to take a "Leap" of faith?
Of course, if it's growth you seek, you need look no further than one of the stocks Wall Street is down grading today to find it. Earlier this week, games maker LeapFrog enterprises beat earnings estimates soundly with a third-quarter report featuring $0.38 per share in profits -- $0.06 better than Wall Street had anticipated. Projections for the future likewise outpaced expectations, with LeapFrog predicting it will earn at least $0.36 per share this year, and perhaps as much as $0.46.
Regardless, analysts at Imperial Capital announced this morning that they are downgrading the stock to "in-line." Why?
According to Imperial, "an increasingly challenging consumer spending environment" and expected "highly promotional and competitive holiday season" all augur poorly for LeapFrog's profits in the current quarter. Although long-term, Imperial remains optimistic about the stock, the analyst is cutting $0.20 per share off its earnings estimates for both this year and next, reducing 2013 estimates to $0.44 per share, and 2014 estimates to $0.55.
If Imperial is right about that, then LeapFrog's current 5.6 "P/E ratio" may not be as big of a bargain as it looks. The $0.44 in earnings per share this year could soon have the stock valued at a P/E of 17.5 (if the stock price does not change), or a slightly less pricey 14 times forward earnings valuation.
And yet, even if Imperial is right about LeapFrog's earnings, I still think the stock's cheap enough to own. Moving from $0.44 to $0.55 in the space of a year implies 25% annualized earnings growth -- more than enough to justify a 17.5 P/E. Indeed, even the more conservative consensus projection for LeapFrog -- 17.5% long-term growth, according to Yahoo! Finance data -- should justify today's price.
Long story short, LeapFrog may not be as big of a bargain as it appears on the surface. But it's still a big enough bargain to buy."
It has a product, has revenues, and that alone is more than MANY MANY other pharmas out there
IMO it SHOULD get back to $2 - $2,50 levels soon
23m in revenues and .53 eps next year is the Yahoo average estimates for next year based on 3 analysts. A 20 p/e would price this at around $10, based on next year's .53 estimates. Do you have the link for your statement that we all could see duh??